Norwalk virus (NV) is the prototype strain of a group of human enteric pathogens recently classified as caliciviruses (22, 29) that are responsible for outbreaks of acute gastroenteritis in the USA and around the world (4, 9). Although NV was visualized by immunoelectron microscopy (IEM) 23 years ago (25), progress in understanding the molecular biology and replication strategies of NV has been hampered by the lack of a cell culture system or an animal model. The host range specificity for this group of viruses appears to be narrow, probably limited to primates and humans. NV is unable to infect experimental animals except for chimpanzees, which undergo an asymptomatic infection (24, 54). A narrow host range also has been suggested for other animal caliciviruses. For example, two closely related strains of rabbit caliciviruses (rabbit hemorrhagic disease virus and European brown hare syndrome virus) that cause lethal liver disease exhibit narrow host tropisms for different species of rabbits (53).
Norwalk virus (NV) is the prototype strain of a group of human enteric pathogens recently classified as caliciviruses (22, 29) that are responsible for outbreaks of acute gastroenteritis in the USA and around the world (4, 9) . Although NV was visualized by immunoelectron microscopy (IEM) 23 years ago (25) , progress in understanding the molecular biology and replication strategies of NV has been hampered by the lack of a cell culture system or an animal model. The host range specificity for this group of viruses appears to be narrow, probably limited to primates and humans. NV is unable to infect experimental animals except for chimpanzees, which undergo an asymptomatic infection (24, 54) . A narrow host range also has been suggested for other animal caliciviruses. For example, two closely related strains of rabbit caliciviruses (rabbit hemorrhagic disease virus and European brown hare syndrome virus) that cause lethal liver disease exhibit narrow host tropisms for different species of rabbits (53) .
The low amounts of virus in stool samples from infected individuals initially delayed understanding the molecular biology of NV. However, in 1990, the first cDNA clones of NV were obtained (19, 32) . Subsequently, the sequence and genomic organization of NV and the closely related Southampton virus were determined (22, 29) . These breakthroughs revealed similarities between the sequence and genomic organization of NV and prototype animal caliciviruses and established these agents as members of the Caliciviridae family (22, 29, 32) . NV and NV-like viruses contain a genome of single-stranded positive-sense RNA of about 7.7 kb which is predicted to encode three open reading frames (ORFs) (22) . The second ORF (ORF2) encodes the capsid protein (apparent molecular weight, 58,000), which is the only structural protein (14, 21) , a property characteristic of the caliciviruses (5) .
The capsid protein of NV spontaneously assembles into recombinant Norwalk virus-like particles (rNV VLPs) when expressed in insect cells infected with a recombinant baculovirus (21) . These empty rNV VLPs can be purified in high yields from the media of infected insect cell cultures. The resulting preparations of rNV VLPs are morphologically and antigenically similar to native virions (13, 21) . The three-dimensional structure of the rNV VLPs has been determined to a resolution of 2.2 nm by electron cryomicroscopy and computer image processing techniques (40) . The single capsid protein folds into three domains to form a shell and protruding arches.
In spite of the recent advances in understanding the genome organization and structure of NV, the lack of a cell culture system continues to limit our ability to dissect the biology of these viruses. We have taken advantage of the ability to purify large amounts of rNV VLPs to study their binding and internalization properties with different cells in culture. These early interactions were studied directly, and after pretreatment with polyclonal and monoclonal antibodies to rNV, to help identify cell lines susceptible to infection and determine if early events in the replication cycle are responsible for the restriction of virus growth in cell cultures and the consequent failure to cultivate this virus in vitro. Among the cell lines chosen for this study are cells from human colon adenocarcinomas, including Caco-2 cells, which upon confluency show morphologic and physiologic markers of differentiation that are characteristic of the mature small intestine enterocytes, also found in fetal human colon. These cells represent the closest in vitro cell culture system available that mimics the in vivo characteristics of human differentiated enterocytes (37) . Human and animal cell lines that have been successfully used to grow fastidious enteric viruses were also tested (36, 38, 46, 48) . Animal cell lines as distantly related as human intestine and insect (Spodoptera frugiperda 9 [Sf9]) ovary were included in this study.
MATERIALS AND METHODS

Cells.
The origins and properties of the cell lines used in this study are listed in Table 1 . The human intestinal cell lines Caco-2 and Int 407 were grown in Earle's minimum essential medium (MEM), supplemented with 10% fetal bovine serum (FBS), L-glutamine, MEM nonessential amino acids, N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES) buffer, penicillin, and streptomycin in a 5% CO 2 incubator. Caco-2 cells were considered undifferentiated (U-Caco-2) at confluency or 1 day postconfluency, when they showed no detectable sucrase activity and domes (structures characteristic of polarized epithelial monolayers undergoing vectorial transport) were lacking. Seven to 14 days postconfluency, Caco-2 cell cultures showed biochemical and morphologic markers of differentiation (sucrase activity of 2.3 to 2.8 mol/mg/h and the presence of domes) and were considered differentiated cultures (D-Caco-2). Porcine kidney LLC-PK cells were grown in MEM with 10% FBS. AGN (primary rhesus kidney) cells were grown in Lebovitz L-15 medium supplemented with 10% FBS, glutamine, penicillin, and streptomycin in a non-CO 2 incubator. Human cell lines HT-29, HCT-8, HL, and HEC were grown in RPMI 1640 supplemented with 10% FBS, penicillin, and streptomycin. Human embryo kidney 293, monkey kidney Vero, and mouse 3T3 E cells were grown in Dulbecco's modified Eagle medium supplemented with 10% FBS, penicillin, and streptomycin. Human T-84 cells were grown in Dulbecco's modified Eagle medium-Ham's F12 medium (1:1 [vol/vol]) supplemented with 10% FBS, penicillin, and streptomycin. Sf9 insect cells were grown in TNM-FH medium containing 10% FBS, penicillin, and streptomycin at 27ЊC.
Preparation of rNV VLPs. rNV VLPs were prepared by infecting Sf9 insect cells (3 ϫ 10 6 cells per ml) at a multiplicity of infection of 10 PFU per cell with the baculovirus recombinant Bac-rNV C8, which expresses the NV capsid protein (21) . Metabolically radiolabeled VLPs were prepared by placing the cells in methionine-free Grace's medium at 28 h postinfection (hpi) for 30 min and then adding 25 to 30 Ci of [ 35 S]methionine (Trans-35 S-label; ICN, Irvine, Calif.) per ml. After 4 to 6 h of labeling, 50 g of unlabeled methionine per ml was added. The cultures were harvested at day 7 postinfection, the cells were pelleted, and rNV VLPs released into the medium were concentrated by centrifugation for 2 h in an SW28 rotor (Beckman) at 26,000 rpm. The pellets were suspended in a solution of CsCl (1.362 g/cm 3 ) and centrifuged for 24 h at 35,000 rpm in a Beckman SW50.1 rotor. Peak fractions of the rNV VLPs were pooled and pelleted for 2 h at 26,000 rpm in an SW28 rotor to remove the CsCl, and the pellets were suspended in 0.01 M phosphate-buffered saline (PBS) and stored at 4ЊC. Pure VLP preparations consisted primarily of 38-nm VLPs (virion-like size). A small proportion of 19-nm VLPs also formed by the NV capsid protein were present in these pure preparations (50) . The 19-nm VLPs were separated from the 38-nm VLPs by sedimentation through 5 to 25% sucrose gradients centrifuged for 3.5 h at 26,000 rpm in a Beckman SW28 rotor. The separated particles were concentrated by pelleting in the same rotor for 3 h at 26,000 rpm. VLP preparations were examined by negative-stain electron microscopy and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). Protein concentration was determined by using the Bio-Rad protein assay (Life Science Research Products, Hercules, Calif.) with bovine gamma globulin as the protein standard. The specific activity of the preparation was determined by calculating the number of counts per minute per microgram of protein.
Antibodies. Polyclonal hyperimmune antisera to rNV VLPs raised in mice, guinea pigs, and rabbits have been described elsewhere (21) . Human pre-and postinfection antisera were obtained from two adult volunteers who seroconverted and excreted NV-specific antigen after being orally inoculated with NV 8FIIa (patients 518 and 520) (12) . Human preinfection antisera were obtained from eight adult volunteers who had NV-specific antibody enzyme-linked immunosorbent assay (ELISA) titers of 5 to 40 and did not seroconvert or excrete antigen after NV inoculation (patients 508, 517, 526, 531, 532, 536, 537, and 553) (12) . Ten immunoglobulin G1 (IgG1) monoclonal antibodies (MAbs) to rNV that have been characterized elsewhere (16) were used (NV834, NV142, NV101, NV813, NV3901, NV3912, NV2461, NV7411, NV8812, and NV8301). These NV-specific MAbs are known to react with rNV by ELISA, IEM, Western blotting (immunoblotting) (WB), and immunoprecipitation (IP). Rotavirus IgG1 MAb 2G4 (45) , which maps to VP5, was used as a control. IgG was purified from ascites fluids by treatment with caprylic acid followed by ammonium sulfate precipitation (33) . The IgG fraction was dialyzed against ammonium bicarbonate, lyophilized, and stored at 4ЊC. The purity of this fraction was confirmed by SDS-PAGE. Working solutions of pure IgG in PBS were made at 2 mg/ml for the blocking experiments. Mouse antipeptide antisera to six NV-specific synthetic peptides, N1, V1, V3, V5, C1, and C2, that localize to amino acid residues 65 to 83, 285 to 305, 336 to 355, 377 to 400, 465 to 484, and 510 to 530 respectively, will be described elsewhere (2) .
Binding assays. Each cell line was grown in monolayers to confluency (or 7 to 14 days postconfluency to obtain D-Caco-2 cells) in 24-or 96-well plates (Costar, Cambridge, Mass.). The cell monolayers were washed three times with cold PBS (pH 7.2) or serum-free Eagle's minimum essential medium (pH 7.2) containing 1% bovine serum albumin, fraction V (BSA; Calbiochem, La Jolla, Calif.) and chilled to 4ЊC. Purified radiolabeled rNV VLPs were added to duplicate wells in serum-free medium-1% BSA at final volumes of 200 l per well in 24-well plates or 30 l per well in 96-well plates. The plates were incubated for 1 h, since the binding plateau was shown at this time, with gentle agitation on a rocker platform at 4ЊC to inhibit internalization. The binding reaction was terminated by gently washing the cells three times with cold PBS containing 0.1% BSA to remove the unbound VLPs, and then the cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (0.15 M NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 1% trasylol, 10 mM Tris-HCl [pH 7.2]). The total radioactivity in the sample was determined by liquid scintillation spectrometry. The number of cells per well was determined for each assay by counting the trypsinized cells from triplicate wells. Assays were done in duplicate and repeated at least twice.
(i) Saturation binding. Dose-response experiments were performed to determine the saturability of binding of rNV VLPs to different cell lines. Increasing amounts of radiolabeled particles (from 0.5 to 40 g/10 5 cells) were added to the confluent monolayers in 24-well plates and incubated for 1 h at 4ЊC in a final volume of 200 l. Each rNV VLP concentration was tested in the presence and absence of a 10-fold excess of unlabeled rNV VLPs to determine the nonspecific and total (specific plus nonspecific) binding, respectively. The specific binding for each rNV VLP concentration was calculated by subtracting the nonspecific binding from the total binding.
(ii) Calculation of cell binding parameters. To calculate cell binding parameters, the number of free rNV VLPs in each well was calculated by subtraction of the number of counts representing the bound VLPs from the VLPs added to the reaction. A Scatchard plot was derived by plotting the bound/free ratio against bound particles, and the best straight-line fit was determined for the results by using regression analyses as previously reported (44) . The intercept of the x axis of the Scatchard plot was multiplied by the amount of particles present in 1 g of purified particles (5.78 ϫ 10 10 ) and then divided by the number of cells in the assay to determine the number of receptor sites per cell. To calculate the number of particles present in 1 g of purified VLPs, the molecular mass of each capsid protein (58 kDa) was multiplied by 180 units forming a particle with an icosahedral symmetry of Tϭ3, times the mass of 1 Da (1.66 ϫ 10 Ϫ24 g). The slope of the line was used to calculate the dissociation constant (K d ), which is equivalent to the inverse of the slope. The value of the slope represented the K d for (iii) Competition of binding. The ability of homologous and heterologous particles to compete with radiolabeled rNV VLPs for binding to the cell surface was determined by incubating confluent monolayers with a mixture of a fixed amount of radiolabeled VLPs (10 g/10 5 cells) and 5-, 10-, or 30-fold-excess unlabeled competitor. The following competitors were tested: homologous rNV VLPs; heterologous rotavirus VP2/6 VLPs made as previously described (8); 19-nm rNV VLPs (see above) (50); soluble NV capsid protein obtained by alkaline dissociation of rNV VLPs (17); and eight high-pressure liquid chromatography (HPLC)-purified synthetic peptides (N1, V1, V2, V3, V4, V5, C1, and C2) that map to different domains on the capsid protein and localize to amino acid residues 65 to 83, 285 to 305, 305 to 333, 336 to 355, 349 to 375, 377 to 400, 465 to 484, and 510 to 530, respectively. The peptides were dissolved in PBS and used in 20-and 200-fold molar excess.
(iv) Blocking of binding. The ability of specific anti-rNV VLP sera (polyclonal, monospecific, and monoclonal) to block the binding of rNV VLPs to Caco-2 and Sf9 cells was examined by preincubating radiolabeled rNV particles (15 g/10 5 cells) with serial dilutions of the antiserum or purified IgG in 0.01 M PBS (final volume, 20 l) for 1 h at 37ЊC. After this mixture was chilled on ice, 10 l of 3% BSA in serum-free MEM was added to each reaction mixture, and the final mixture was added to confluent monolayers in 96-well plates that had been prewashed with cold serum-free MEM-1% BSA. Binding was assayed as described above.
Internalization assays. Internalization assays were carried out in triplicate as described by Bass et al. (3), with slight modifications. Briefly, radiolabeled rNV VLPs (70 g/10 5 cells) were bound to confluent monolayers in 96-well plates for 1 h at 4ЊC, washed twice with serum-free MEM, and transferred to 37ЊC to allow internalization to occur. Following a 1-to 4-h incubation, the cells were washed twice in cold PBS, treated with proteinase K (500 g/ml; Boehringer Mannheim, Mannheim, Germany) for 30 min at 4ЊC, washed three times with ice-cold PBS-0.1% BSA, and solubilized in RIPA buffer, and the cell-associated radioactivity was quantitated by scintillation counting. The efficiency of the proteinase K treatment to remove surface bound VLPs was determined in control plates kept at 4ЊC, instead of 37ЊC, to prevent internalization of the VLPs. These control experiments showed that 94 to 98% of the VLPs bound at 4ЊC were digested under these conditions. Specificity was assayed by the addition of a 10-fold excess of unlabeled rNV VLPs.
Preparation of N-terminal and C-terminal truncated forms of the capsid protein. Baculovirus transfer plasmids containing only the full-length gene of the NV capsid protein and the four truncated mutants were generated by inserting PCR-amplified fragments flanked by restriction enzyme sites BglII and BamHI into those sites in the transfer vector pVL 1393 (Invitrogen, San Diego, Calif.). The template used for PCR in all cases was the plasmid pGNV, which contains the NV ORF2, as described previously (21) . The PCR for the full-length capsid protein gene amplified a segment corresponding to nucleotides (nt) 5349 to 6976 by using primers NV-110a and NV-111a (5Ј-GCGGCGAGATCTAATTCGTA AATGATGATGGCG-3Ј and 5Ј-GCGGCGAGATCTAATTGCACCAATTAT GGCTT-3Ј). The N-terminal truncated form, NT 35 , included nt 5461 to 6976 and was amplified by PCR by using primers NV-102 (5Ј-CCGGGGATCCATGGCT GTAGCAGGTTCTTCGACA-3Ј) and NV-109 (5Ј-CCCGGGGGATCCAATT GCACCAATTATGGCTT-3Ј). The expressed capsid protein from this clone lacks the N-terminal 35 amino acids, and the dipeptide methionine-alanine has been added to the N terminus. The N-terminal truncated gene NT 98 spans from nt 5456 to 6976 and was amplified by using primers NV-106 (5Ј-CCCGGGGG ATCCCTAAATGATGATGGCGTCTAA-3Ј) and oligonucleotide NV-109. The final clone starts at a BamHI site internal to the site on the primer, and the expressed protein from this clone starts at the methionine in position 99. The C-terminal truncated capsid gene CT 230 , which expressed a protein with the C-terminal 230 amino acid residues deleted, was amplified by using primer NV-110a and primer NV-114a (5Ј-GCGGCGAGATCTTCAGTTGATTACAG TGCCATT-3Ј). A double deletion mutant, NCT 98/146 , spanning from nt 5456 to 6510, expressed a protein containing amino acids 99 to 384. The primers used to amplify this fragment were NV-106 and NV-108a (5Ј-AAAAAAGGATCCTCA GCCAGACGGGTGTGATGGGG-3Ј). The PCR products were digested with BglII and ligated to the BglII-linearized, calf intestine alkaline phosphatasetreated pVL 1393 transfer vector (Invitrogen). The insertion site junctions were confirmed to be correct by sequencing. Baculovirus recombinants containing the complete or truncated forms of NV ORF2 were prepared by cotransfecting Sf9 insect cells with the pVL 1393 recombinant plasmids along with Baculogold (Invitrogen) as described previously (8) . The recombinant viruses were identified by slot blot hybridization followed by two rounds of plaque purification. 35 S-labeled full-length or truncated NV capsid protein was expressed in Sf9 cells infected with the respective baculovirus recombinant. The cells were labeled with 25 Ci/ml at 28 hpi and harvested at 36 hpi. Cell lysates were prepared for IP as described previously (16) . The expression of the full-length and truncated proteins was confirmed by WB and IP, using rabbit polyclonal antisera to rNV.
Mapping the MAb binding site by IP of truncated forms of the NV capsid protein. Sf9 cell lysates containing 35 S-labeled full-length and truncated forms of the capsid protein (NT 35 , NT 98 , CT 230 , and NCT 98/146 ) corresponding to 10 5 cpm were immunoprecipitated in nondenaturing buffer with MAb NV8812 and a rabbit polyclonal antisera to rNV (diluted 1:20 and 1:50) as described previously (16) . In some cases, the 32-kDa (32K) C-terminal trypsin cleavage product of the rNV protein was prepared as described before (16) and used in the IP assays. Briefly, 35 S-labeled rNV VLPs were dissociated by incubation in 10 mM Tris-HCl (pH 9.0) and then digested with 250 g of trypsin (Worthington Biochemical, Freehold, N.J.) per ml for 1 h at 37ЊC.
RESULTS
Two major criteria are commonly used to determine the specificity of virus-receptor interactions. Specific binding should be (i) saturable and (ii) competitively inhibited by a second ligand (unlabeled virus) known to bind to the same receptor.
Binding of rNV VLPs to cells is saturable and specific. Classic binding kinetics were used to study the binding of rNV VLPs to different cells in culture and determine if the binding occurred through a finite number of specific molecules on the cell surface. Dose-response curves of rNV VLPs binding to D-Caco-2, U-Caco-2, and Sf9 cells are shown in Fig. 1A to C. Nonspecific binding measured in the presence of 10-fold-excess unlabeled particles was a small fraction of the total binding and showed a linear relationship between the amount of radiolabeled VLPs added and the amount bound for the three cell lines. The specific binding for each concentration of radiolabeled particles was calculated by subtracting the nonspecific from the total binding. Scatchard plot analysis of the specific saturable binding of rNV VLPs for each cell line (Fig. 1D) showed that the K d calculated from the slope of the curve was within the same range for the three cell cultures (10 Ϫ8 to 10 One approach to address if the apparent narrow host range of NV infection results from the presence of specific receptors that are restricted to cell populations in the human intestine was to compare the binding of rNV VLPs to human intestinal cell lines with binding to other human and animal cell lines. Cells from different origins (Table 1) , grown to confluent monolayers in 24-well plates, were incubated with varied amounts (5 to 10 g/200 l/10 5 cells) of 35 S-Trans-label-radiolabeled VLPs for 1 h at 4ЊC. rNV VLPs bound to every cell line tested; the percentage of input virus that remained associated with the cells ranged from 1 to 19% (Fig. 2) . A fraction of this binding was not competed for by unlabeled rNV VLPs, representing nonspecific binding. Dose-response curves of the binding of rNV VLPs to these cell lines also showed saturation (data not shown), indicating that VLPs bind to a finite number of specific binding sites on the surfaces of all of the different cell lines tested. Five of the cell lines tested originated from human colon carcinomas. Among them, D-Caco-2 bound more VLPs than the other cell lines. Binding did not seem to correlate with a particular tissue or species of origin of the cell lines. The binding and internalization of rNV VLPs to DCaco-2 cells were not affected significantly when the cells were pretreated with trypsin (0.25 to 8 g/ml; Worthington) or pancreatin (50 to 100 g/ml; Gibco BRL) for 1 h at 4ЊC (data not shown). 
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The binding of rNV VLPs is competed for by homologous particles but not by heterologous particles. To further examine the specificity of the rNV binding to the different cultured cells, we compared the abilities of unlabeled homologous rNV VLPs and heterologous rotavirus VP2/6 VLPs to compete with radiolabeled rNV VLPs for binding to specific cell surface molecules. A 10-fold excess of unlabeled rNV VLPs abolished 83 and 76% of the binding of radiolabeled rNV VLPs to D-and U-Caco-2 cells, respectively, while rotavirus VP2/6 VLPs abolished only 7 and 8%, respectively, of the binding (Fig. 3A) . The competition of binding to Sf9 cells by unlabeled rNV VLPs was similar to that of Caco-2 cells (77%). Unexpectedly, unlabeled rotavirus VP2/6 VLPs appeared to compete for some binding sites on Sf9 cells (34%), suggesting that the binding of rNV VLPs to Sf9 cells may have properties different from those of the binding to Caco-2 cells. Figure 3B shows the binding to D-Caco-2 cells in the presence of other competitors. A 10-fold excess of unlabeled purified 19-nm rNV VLPs was able to compete with the binding of radiolabeled 38-nm rNV VLPs to D-Caco-2 cells, suggesting that the virus attachment site is conserved in VLP structures of both sizes. The 19-nm VLPs are assembled in Sf9 cell cultures along with the 38-nm VLPs when the NV capsid protein is expressed in the baculovirus expression system. SDS-PAGE analysis has indicated that 19-nm VLPs, like the 38-nm VLPs, are formed by the NV capsid protein (50) . Smaller empty particles have been found in preparations of VLPs from a Mexican strain of human calicivirus, MX virus (20) , and in human stool samples containing typical human calicivirus particles (49) . Soluble NV Table 1. capsid protein obtained by alkaline dissociation of purified rNV VLPs (17) also competed with rNV VLPs for binding sites on D-Caco-2 cells. These results indicate that the correct conformation of the virus attachment site on the NV capsid protein is present in the dissociated soluble forms.
NV-specific synthetic peptides do not block binding. Eight HPLC-purified NV synthetic peptides that map to different domains on the NV capsid protein were tested for the ability to compete with radiolabeled rNV VLPs for specific binding sites on the surface of Caco-2 cells (see Fig. 6A ). The sequences of five of these peptides cover the region on the capsid protein between amino acids 285 and 400, which is predicted to contain the binding site for MAb NV8812 (see below). Binding of radiolabeled rNV VLPs was not altered when a 20-or 200-fold molar excess of the purified peptides was used in the competition assays (data not shown), suggesting that the virus attachment site on the capsid protein is conformational. In agreement with this finding MAb NV8812 did not react with any of the NV peptides when tested by ELISA (2). These results suggest that MAb NV8812 binds to a conformational epitope, as shown earlier by Hardy et al. (16) .
Internalization of radiolabeled rNV VLPs by human and insect cell lines. We determined whether the rNV VLPs were internalized as a consequence of their specific binding to the surface of D-Caco-2, U-Caco-2, T-84, and Sf9 cells. The internalization assay was designed to determine how much of the bound VLPs entered the cells by allowing prebound radiolabeled VLPs to enter the cells by warming them to 37ЊC. After 1 h, surface-bound particles were removed by proteinase K digestion. The treatment of cells with proteinase K to remove surface-bound particles was effective in reproducibly removing 94 to 98% of the counts attached to the cell surface in control cells kept at 4ЊC before the proteinase K treatment. The average counts from internalization controls kept at 4ЊC prior to proteinase K treatment were subtracted from the internalized counts. Between 1.4 and 6.8% of the counts bound to the four cell cultures remained associated with the cells after the proteinase K treatment (Fig. 4) . To exclude the possibility that the low levels of entry measured were a consequence of nonspecific binding, the internalization assays were done in the presence of a 10-fold excess unlabeled rNV VLPs. Under these conditions, no counts were detected inside the cells by our assay, indicating that the entry was a consequence of specific binding (data not shown). Our assay was validated by showing that it was able to detect 15% of 35 S-labeled rotavirus SA11 4F internalized into D-Caco-2 cells after 30% of the input virus was bound to the cell surface. Internalization of rotavirus SA11 4F was blocked (56% inhibition) in the presence of a 10-fold excess of unlabeled virus (data not shown). (45) and IgG from MAbs NV3901 and NV3912 had no blocking activity (Fig. 5) . MAb NV8812 IgG also blocked binding to Sf9 cells (data not shown). These MAbs to rNV VLPs have been assigned to three groups based on their differential reactivities (16) . MAb NV8812 is one of three group III MAbs that recognize discontinuous epitopes located in the C-terminal 230 residues of the capsid protein. Another group III MAb (NV8301) exhibited intermediate levels of blocking activity, suggesting that it may map to residues that partially overlap or are close to the site recognized by MAb NV8812. We hypothesize that the site recognized by MAb NV8812 is involved in the attachment of rNV VLPs to cells. Polyclonal antisera to rNV VLPs do not block binding. Three polyclonal hyperimmune sera produced in our laboratory against purified rNV VLPs were tested for the ability to block the specific binding of rNV VLPs to D-Caco-2 cells. These hyperimmune antisera from rabbits, mice, and guinea pigs immunized with three intramuscular injections of purified rNV have a high (Ͼ10 6 ) titer to rNV VLPs by ELISA and can detect NV in stools from infected persons by an antigen capture ELISA (12, 21) . These antisera also bind to rNV VLPs and to native NV following analysis by IEM, IP, and WB (21) . We tested the ability of serial dilutions (1:20 to 1:4,000) of the antisera to block virus binding to cells. None of the antisera tested significantly inhibited or enhanced binding of rNV VLPs to D-Caco-2 cells (data not shown). Binding also was not blocked by human pre-and postinfection sera from two adult volunteers who seroconverted and excreted antigen in stools after being orally inoculated with NV 8FIIa (12) . rNV VLP binding to cells also was not blocked by preinoculation sera from an additional eight patients who were resistant to infection (no seroconversion or antigen excretion) with the 8FIIa NV inoculum.
NV-specific MAb blocks binding of rNV VLPs to D-Caco-2 and Sf9 cells. Ten MAbs developed against rNV
Monospecific polyclonal antisera directed against synthetic peptides that map to known residues on the capsid protein do not block rNV VLP binding to cells. Hyperimmune antisera to six NV capsid protein synthetic peptides (amino acid residues 65 to 83, 285 to 305, 336 to 355, 377 to 400, 465 to 484, and 510 to 530) produced in mice and guinea pigs (2) were not able to block the binding of rNV VLPs to D-Caco-2 cells when tested in blocking experiments at dilutions of 1:50, 1:100, and 1:400 (data not shown).
Mapping the binding site of MAb NV8812. Since MAb NV8812 blocked attachment presumably by binding to the virus attachment site on the rNV VLP capsid protein, we pursued localizing the binding site of this MAb. The reactivity of MAb NV8812 was tested by IP with different truncated forms of the rNV capsid protein and the 32K C-terminal trypsin cleavage fragment of the capsid protein (Fig. 6) . Under conditions that would keep the protein properly folded during the assay (16), the hyperimmune polyclonal rabbit sera to rNV VLPs recognized all of the different forms of the capsid protein. MAb NV8812 reacted with the 32K trypsin cleavage product, with the N-terminal truncated forms NT 35 and NT 98 , and with the double N-and C-terminal truncated fragment NCT 98/ 146. MAb NV8812 did not recognize CT 230 in this assay (Fig.  6) . These results suggest that MAb NV8812 binds to a conformational epitope on the capsid protein located between amino acid residues 300 and 384. We hypothesize that the virus attachment site also maps in this region.
DISCUSSION
The initial step in a virus infectious cycle is the attachment of the virion to the host cell membrane. For many viruses such as human immunodeficiency virus and rhinovirus, virus attachment occurs through a specific receptor molecule present in a finite number of sites that mediates a high-affinity interaction (7, 15, 28) . At the other end of the spectrum, other viruses like Semliki Forest virus (18) have low-affinity interactions with cell surface molecules present in many copies on the cell surface, and a less specific interaction leads to a productive infection. It has been demonstrated for several viral systems that the adsorption step is a major determinant of the host range and tissue tropism of the virus (6, 28, 43) , and usually a narrow host range has been associated with high-affinity interactions with a very specific receptor (31) . Because of the apparent narrow host range of NV and the inability to grow this virus in tissue culture, we hypothesized that early events in its replication cycle could determine the host range specificity and the failure of virus to grow in cell culture.
For viruses that lack a cell culture system, the use of recombinant VLPs to study early events in the replication cycle is an alternative approach to examine binding and internalization for a variety of cell lines. Data from such studies can unravel the potential role of these interactions in the inability to grow the virus in cell culture and in host specificity. For example, this approach was used by Müller et al. (34) to study the initial interactions of epitheliotropic papillomaviruses (PVs), which are unable to complete their entire life cycle in cell culture (47) . These investigators reported that bovine PV (BPV) synthetic capsids and BPV virions bound to the same receptor molecules in cultured cells from different origins, suggesting that empty VLPs behaved like authentic virions in their interaction with the cell surface of a wide range of cells. Their results suggested that the PV receptor is a conserved cell surface molecule used by human PV and BPV VLPs and that the tropism of infection by different PVs is controlled by events downstream from the initial steps of binding and uptake (41) .
Our initial approach to study human calicivirus-host cell interactions is based on the assumption that the virus attachment site on the rNV is functionally equivalent to that on the infectious virions. The following observations support this assumption. (i) VLPs are antigenically similar to authentic virions, as determined by cross-reactivity in ELISAs and IPs using NV-specific hyperimmune antisera, MAbs, and antipeptide antisera (13, 16, 21) . (ii) Comparison of computer-reconstructed images at 2.2-nm resolution of rNV VLPs and a primate calicivirus virion containing genomic RNA (39, 40) indicated that the absence of nucleic acid in the rNV VLPs does not alter the general domain organization of the particle. (iii) The ability of the rNV capsid protein to self-assemble into empty capsids suggests that protein-protein interactions, more than RNAprotein interactions, are responsible for assembling the correct NV capsid structure.
Our results show that radiolabeled rNV VLPs bind to a saturable number of specific molecules on the surfaces of the human and animal cells tested. Variations in the amount of VLPs bound among the cell lines did not correlate with tissue or species of origin. Scatchard plot analyses revealed similar binding affinities for human and animal cells, with values in the range previously described for virus-receptor interactions (10 8 to 10 Specific saturable binding of virions or VLPs to the cell surface does not necessarily result in viral uptake. Some viruses require interaction(s) with more than one cellular surface molecule to initiate a productive infection (30, 52) . In our study, the specific binding of rNV VLPs to human and animal cell lines led to low levels of internalization (1.4 to 6.8%). The percentages of particles internalized by the different cell lines were not significantly different, but internalization was inhib- ited by excess unlabeled rNV VLPs, indicating that the low levels of internalization observed were due to the entry of a small fraction of specifically bound VLPs. The ability of our assay to detect viral entry into Caco-2 cells was confirmed by measuring the internalization of radiolabeled purified rotavirus. Our assay showed that 15% of bound rotavirus was internalized, validating the assay. However, because of the low efficiencies of internalization of rNV VLPs, we cannot rule out the possibility that nonspecific pinocytosis is the mechanism responsible for the entry levels measured by our assay. Without having a cultivation system, our present data cannot distinguish whether the small amount of internalization is sufficient to initiate replication, or if this represents the block to replication in cell culture. If entry is the block, experimental manipulations to enhance entry might facilitate virus cultivation. Very little is known about the early interactions of other caliciviruses with cells and host tropism. The binding and entry characteristics of only feline calicivirus (FCV) have been examined (26, 27) . FCV was shown to bind efficiently (40 to 80%) to permissive cells and less efficiently (20%) to nonpermissive cells (27) . Infectious virus was recovered after transfection of FCV RNA into nonpermissive cells, suggesting that FCV replication in nonpermissive cells is primarily restricted by the absence of appropriate receptors on the cell surface (27) . This interpretation is consistent with available data, although internalization, penetration, and uncoating of particles were not examined. Therefore, it is possible that one of these other early events plays a role in the growth restriction of FCV in nonpermissive cells. Entry of FCV to permissive cells appeared to require a low-pH-dependent pathway (26) .
If these data with FCV are relevant to all caliciviruses, one interpretation of our results is that the low efficiency of binding and internalization of rNV to the cell lines tested is due to the absence of the appropriate receptors on the surface of those cells. If this interpretation is correct, other cells in the intestine, different from the mature differentiated enterocytes, could be the ones susceptible to NV infection. Permissive cells would show higher binding and internalization efficiencies than those observed in this study. Alternatively, enterocyte function might be modified in the intestine in response to interactions with diverse adjacent cells or signals from these cells. In that case, our results could be a consequence of the inability of the cell culture systems available to simulate the in vivo environment and terminal stage of differentiation required for the productive attachment and entry of NV into the host cell. Flynn and Saif (10) have reported the successful in vitro serial propagation of a porcine calicivirus in primary porcine kidney cells. This occurred only in the presence of intestinal contents from uninfected gnotobiotic piglets, suggesting that the lack of specific in vivo conditions in in vitro systems may limit the binding, internalization and/or later events in the replication cycle. When we pretreated D-Caco-2 cells with different concentrations of trypsin and pancreatin, the binding or internalization to those cells was not affected significantly, suggesting that other factors may be required to achieve successful cultivation.
Our data show that D-Caco-2 cells bind rNV VLPs most efficiently and probably internalize enough particles to initiate a productive infection. These may be an appropriate cell culture for virus cultivation. However, our data also indicate that NV capsid soluble protein present in stools competes for particle binding to cells. Successful virus cultivation may require removal of this soluble protein prior to cultivation attempts.
The specific binding of a virus to its cellular receptor can usually be blocked by polyclonal antisera raised against the virion and/or by MAbs to the virus attachment site. Exceptions to this blocking effect have been reported for picornaviruses that have developed different strategies to avoid recognition of the virus attachment site by the host immune system, such that neutralizing antibodies do not block virus binding. For enteroviruses and rhinoviruses, the virus attachment site is located in a cleft or canyon on the virus surface (42), where antibodies are not able to interact because of steric hindrance. For footand-mouth disease virus, an RGD conserved sequence in the C terminus of VP1, surrounded by hypervariable residues, has been proposed as the virus attachment site (11) . This site is associated with a flexible structural component or disordered loop that hinders the immune system from recognizing the epitope (1) .
Our experiments found that one MAb made to rNV VLPs blocked binding of rNV VLPs to Caco-2 and Sf9 cells, while polyclonal hyperimmune antiserum to rNV VLPs and human serum from infected individuals failed to block binding. The inability of polyclonal antiserum to rNV to block specific binding to human intestinal cell lines can be interpreted as a consequence of a poor accessibility of the virus attachment site to interact with antibody molecules, either because of its location in a structural cleft, similar to enteroviruses and rhinoviruses (42) , or possibly because the virus attachment site is a disordered structure as reported for foot-and-mouth disease virus (1) . Another factor that may explain the inability of the rNV polyclonal antisera to block binding is its suspected monospecificity. For example, the polyclonal hyperimmune antiserum to rNV made in our laboratory is type specific, recognizing only NV or strains of the same serotype in ELISAs (21) . This finding suggests that the antibodies in the polyclonal sera recognize a few immunodominant epitopes in the capsid protein of NV. In light of these results, the reported lack of correlation between preexisting serum antibodies to NV and protection against disease in human volunteers challenged with NV (23, 35) could be explained by the absence of antibodies that block attachment. Short-term clinical immunity has been found in adult volunteers after multiple challenges with NV, but it is not clear what the correlates of this short-term protection are. It is possible that repeated exposures are required to induce an antibody response capable of blocking the binding of virions to the target cells.
The reactivity of MAb NV8812 with truncated mutants and trypsin-cleaved forms of the capsid protein by IP indicates that the binding site for this MAb is between amino acid residues 300 and 384 in the C terminus of NV capsid protein. This assignment is made with the caveat that the lack of binding of MAb NV8812 to the CT 230 construct is not influenced by conformational changes caused by removal of the C terminus. If it is, the binding site should be between amino acids 228 and 384. On the basis of predictions derived from structural studies of rNV VLPs (40) , it is likely that these residues form part of the arch-like structures in the rNV capsids. We propose that the NV capsid protein amino acid residues from 300 to 384 contain a domain involved in the specific binding to Caco-2 cells as well as to other animal cell lines. This hypothesis and the biological relevance of this site will be confirmed if this MAb blocks NV replication in volunteers or blocks replication in culture once NV is successfully cultivated.
